BNGO — BioNano Genomics Income Statement
0.000.00%
Last trade - 00:00
- $37.00m
- $21.88m
- $36.12m
2019 December 31st | R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 10.1 | 8.5 | 18 | 27.8 | 36.1 |
Cost of Revenue | |||||
Gross Profit | 3.36 | 2.77 | 3.87 | 5.95 | 9.57 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 37.3 | 47.1 | 95.4 | 160 | 251 |
Operating Profit | -27.2 | -38.6 | -77.4 | -132 | -215 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -29.8 | -41.1 | -78.2 | -131 | -232 |
Provision for Income Taxes | |||||
Net Income After Taxes | -29.8 | -41.1 | -72.4 | -133 | -232 |
Net Income Before Extraordinary Items | |||||
Net Income | -29.8 | -41.1 | -72.4 | -133 | -232 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -29.8 | -41.1 | -72.4 | -133 | -232 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -19.3 | -3.85 | -2.57 | -4.54 | -5.34 |